Besponsa .25 mg/mL (Inotuzumab Ozogamicin INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) .25 mg/mL

Besponsa (inotuzumab ozogamicin) is a targeted therapy used in cancer treatment. This lyophilized powder for injection is designed for intravenous administration and is available in a 0.25 mg/mL strength.

Strength

.25 mg/mL

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (0008-0100-01) / 4 mL in 1 VIAL, SINGLE-DOSE

Manufacturer / TM Owner

Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Besponsa is primarily used in the treatment of certain types of cancer. It works by targeting specific cells in the body, which may help in managing the disease. Patients often wonder, 'What is Besponsa used for?' and it is typically prescribed for conditions where targeted therapy is beneficial.

Side Effects

Besponsa may cause various effects, including fatigue, nausea, and fever. Some patients may experience more severe reactions, so it is important to monitor for any unusual symptoms. The specific effects can vary from person to person.

Precautions & Warnings

Besponsa should be handled with care, as it is a potent medication. It is essential to follow the prescribed dosage and administration guidelines provided by a healthcare professional. Proper storage and handling are crucial to maintain the medication's effectiveness.

Avoid Interactions

Besponsa may interact with other medications, including those that affect the immune system. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also affect how Besponsa works.

Frequently Asked Questions

Besponsa is used in the treatment of certain types of cancer, targeting specific cells in the body.

Besponsa is administered intravenously after being reconstituted from its lyophilized powder form.

Common side effects may include fatigue, nausea, and fever, though individual experiences can vary.

Besponsa may interact with other medications, so it is important to consult a healthcare provider before combining treatments.

Besponsa should be stored according to the manufacturer's guidelines to maintain its effectiveness.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.